These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29903413)

  • 1. Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
    Richards MR; Guo T; Hunter CD; Cairo CW
    Bioorg Med Chem; 2018 Oct; 26(19):5349-5358. PubMed ID: 29903413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes.
    Albohy A; Mohan S; Zheng RB; Pinto BM; Cairo CW
    Bioorg Med Chem; 2011 May; 19(9):2817-22. PubMed ID: 21489803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of selective inhibitors for human neuraminidase isoenzymes using C4,C7-modified 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) analogues.
    Zhang Y; Albohy A; Zou Y; Smutova V; Pshezhetsky AV; Cairo CW
    J Med Chem; 2013 Apr; 56(7):2948-58. PubMed ID: 23530623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
    Pan P; Li L; Li Y; Li D; Hou T
    Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
    Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
    J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homology modeling of human sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: hints for the design of selective NEU3 inhibitors.
    Magesh S; Suzuki T; Miyagi T; Ishida H; Kiso M
    J Mol Graph Model; 2006 Oct; 25(2):196-207. PubMed ID: 16427342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidases as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay.
    Quosdorf S; Schuetz A; Kolodziej H
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29149072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
    Malaisree M; Rungrotmongkol T; Decha P; Intharathep P; Aruksakunwong O; Hannongbua S
    Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
    Singh A; Soliman ME
    Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoenzyme-Selective Inhibitors of Human Neuraminidases Reveal Distinct Effects on Cell Migration.
    Howlader MA; Guo T; Chakraberty R; Cairo CW
    ACS Chem Biol; 2020 Jun; 15(6):1328-1339. PubMed ID: 32310634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors.
    Cheng LP; Wang TC; Yu R; Li M; Huang JW
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3622-3629. PubMed ID: 30389293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NEU1-selective sialidase inhibitor, C9-butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo.
    Hyun SW; Liu A; Liu Z; Cross AS; Verceles AC; Magesh S; Kommagalla Y; Kona C; Ando H; Luzina IG; Atamas SP; Piepenbrink KH; Sundberg EJ; Guang W; Ishida H; Lillehoj EP; Goldblum SE
    Glycobiology; 2016 Aug; 26(8):834-49. PubMed ID: 27226251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five Novel Non-Sialic Acid-Like Scaffolds Inhibit In Vitro H1N1 and H5N2 Neuraminidase Activity of Influenza a Virus.
    Márquez-Domínguez L; Reyes-Leyva J; Herrera-Camacho I; Santos-López G; Scior T
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32947893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Effect of Neuraminidase-1-Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis.
    Luzina IG; Lillehoj EP; Lockatell V; Hyun SW; Lugkey KN; Imamura A; Ishida H; Cairo CW; Atamas SP; Goldblum SE
    J Pharmacol Exp Ther; 2021 Jan; 376(1):136-146. PubMed ID: 33139318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.
    Murrell MT; Porotto M; Greengard O; Poltoratskaia N; Moscona A
    J Virol; 2001 Jul; 75(14):6310-20. PubMed ID: 11413297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors.
    Das A; Adak AK; Ponnapalli K; Lin CH; Hsu KC; Yang JM; Hsu TA; Lin CC
    Eur J Med Chem; 2016 Nov; 123():397-406. PubMed ID: 27487569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
    Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.
    Barrett S; McKimm-Breschkin JL
    Antiviral Res; 2014 Aug; 108():30-5. PubMed ID: 24854981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiscale Simulation of Receptor-Drug Association Kinetics: Application to Neuraminidase Inhibitors.
    Zeller F; Luitz MP; Bomblies R; Zacharias M
    J Chem Theory Comput; 2017 Oct; 13(10):5097-5105. PubMed ID: 28820938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
    Prachanronarong KL; Özen A; Thayer KM; Yilmaz LS; Zeldovich KB; Bolon DN; Kowalik TF; Jensen JD; Finberg RW; Wang JP; Kurt-Yilmaz N; Schiffer CA
    J Chem Theory Comput; 2016 Dec; 12(12):6098-6108. PubMed ID: 27951676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.